Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 201

1.

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.

Mov Disord. 2018 Dec 21. doi: 10.1002/mds.27565. [Epub ahead of print]

PMID:
30575996
2.

Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?

Fox SH, Brotchie JM.

Eur J Neurosci. 2018 Sep 30. doi: 10.1111/ejn.14173. [Epub ahead of print]

PMID:
30269407
3.

Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.

Brigham EF, Johnston TH, Brown C, Holt JDS, Fox SH, Hill MP, Howson PA, Brotchie JM, Nguyen JT.

J Pharmacol Exp Ther. 2018 Nov;367(2):373-381. doi: 10.1124/jpet.118.247650. Epub 2018 Aug 7.

PMID:
30087157
4.

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.

Johnston TH, Lacoste AMB, Visanji NP, Lang AE, Fox SH, Brotchie JM.

Neuropharmacology. 2018 Jun 1. pii: S0028-3908(18)30270-3. doi: 10.1016/j.neuropharm.2018.05.035. [Epub ahead of print] Review.

PMID:
29907424
5.

A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.

Henrich MT, Geibl FF, Lee B, Chiu WH, Koprich JB, Brotchie JM, Timmermann L, Decher N, Matschke LA, Oertel WH.

Acta Neuropathol Commun. 2018 May 10;6(1):39. doi: 10.1186/s40478-018-0541-1.

6.

Corrigendum to "Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism" [Neurobiol. Dis. 106 (2018) 133-146].

Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JEM, Najarali Z, Hassan Khan M, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE.

Neurobiol Dis. 2018 Aug;116:180. doi: 10.1016/j.nbd.2018.02.018. Epub 2018 Mar 20. No abstract available.

PMID:
29571591
7.

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM.

Neuropharmacology. 2018 Mar 15;131:116-127. doi: 10.1016/j.neuropharm.2017.11.046. Epub 2017 Nov 29.

PMID:
29197517
8.

Reply to "Can STN DBS protect both nigral somata and innervation of the striatum?"

Koprich JB, Brotchie JM, Musacchio T, Volkmann J, Ip CW.

Ann Neurol. 2017 Nov;82(5):856. doi: 10.1002/ana.25066. Epub 2017 Oct 26. No abstract available.

PMID:
28985651
9.

Animal models of α-synucleinopathy for Parkinson disease drug development.

Koprich JB, Kalia LV, Brotchie JM.

Nat Rev Neurosci. 2017 Sep;18(9):515-529. doi: 10.1038/nrn.2017.75. Epub 2017 Jul 13. Review.

PMID:
28747776
10.

Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism.

Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JHM, Najarali Z, Khan MH, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE.

Neurobiol Dis. 2017 Oct;106:133-146. doi: 10.1016/j.nbd.2017.06.009. Epub 2017 Jul 1. Erratum in: Neurobiol Dis. 2018 Mar 20;:.

PMID:
28673739
11.

Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.

Musacchio T, Rebenstorff M, Fluri F, Brotchie JM, Volkmann J, Koprich JB, Ip CW.

Ann Neurol. 2017 Jun;81(6):825-836. doi: 10.1002/ana.24947. Epub 2017 Jun 9.

12.

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.

Ip CW, Klaus LC, Karikari AA, Visanji NP, Brotchie JM, Lang AE, Volkmann J, Koprich JB.

Acta Neuropathol Commun. 2017 Feb 1;5(1):11. doi: 10.1186/s40478-017-0416-x.

14.

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.

Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, Lang AE.

Trends Neurosci. 2016 Nov;39(11):750-762. doi: 10.1016/j.tins.2016.09.003. Epub 2016 Oct 21. Review.

PMID:
27776749
15.

Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury.

Ip CW, Isaias IU, Kusche-Tekin BB, Klein D, Groh J, O'Leary A, Knorr S, Higuchi T, Koprich JB, Brotchie JM, Toyka KV, Reif A, Volkmann J.

Acta Neuropathol Commun. 2016 Oct 3;4(1):108.

16.

Reference ranges of peripheral blood lymphoid subsets by 10-colour flow cytometry based on 69 healthy adults from Australia.

Brotchie J, Chapple P, Came N, Liew D, Juneja S.

Pathology. 2016 Oct;48(6):631-4. doi: 10.1016/j.pathol.2016.06.005. Epub 2016 Sep 2. No abstract available.

PMID:
27596237
17.

Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of Nonhuman Primate Studies and Clinical Trials.

Huot P, Fox SH, Brotchie JM.

J Pharmacol Exp Ther. 2016 Jun;357(3):562-9. doi: 10.1124/jpet.116.232371. Epub 2016 Apr 13. Review.

PMID:
27190169
18.

Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.

Ma Y, Johnston TH, Peng S, Zuo C, Koprich JB, Fox SH, Guan Y, Eidelberg D, Brotchie JM.

Mov Disord. 2015 Aug;30(9):1283-8. doi: 10.1002/mds.26302.

19.

The link between mitochondrial complex I and brain-derived neurotrophic factor in SH-SY5Y cells--The potential of JNX1001 as a therapeutic agent.

Kim HK, Mendonça KM, Howson PA, Brotchie JM, Andreazza AC.

Eur J Pharmacol. 2015 Oct 5;764:379-84. doi: 10.1016/j.ejphar.2015.07.013. Epub 2015 Jul 8.

PMID:
26164791
20.

The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.

Huot P, Johnston TH, Fox SH, Newman-Tancredi A, Brotchie JM.

Neuropharmacology. 2015 Oct;97:306-11. doi: 10.1016/j.neuropharm.2015.05.033. Epub 2015 Jun 10.

PMID:
26071982

Supplemental Content

Loading ...
Support Center